BCL-2 protein family: attractive targets for cancer therapy.
Kaloni D, Diepstraten ST, Strasser A, Kelly GL. · 2023
Read BCL-2 protein family: attractive targets for cancer therapy. by Kaloni D, Diepstraten ST, Strasser A, Kelly GL. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9950219.txt.
Description
Kaloni and co-authors review the BCL-2 protein family as a target for cancer therapy. Escape from cell death is a hallmark of cancer. BCL-2 family proteins control apoptotic death, the main self-destruct route. Tumors often raise pro-survival members or cut pro-death ones.
Both shifts block apoptosis and appear in many cancers. The review covers each family member's role in normal growth and body function. It shows how lost death control aids cancer growth and therapy resistance. Drugs called BH3-mimetics block pro-survival BCL-2 proteins. Their development as new cancer agents is discussed in detail. The authors frame the family as a rich source of drug targets. Readers get biology and therapy in one account.
Catalog record
| CREATOR | Kaloni D, Diepstraten ST, Strasser A, Kelly GL. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |